National Institute for Health and Care Excellence

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

The evaluation committee considered evidence submitted by Takeda and a review of this submission by the external assessment group (EAG). See the committee papers for full details of the evidence.
FiercePharma

FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. market, GSK has suffered a serious setback at the hands of the FDA’s Oncologic Drugs Advisory Committee (ODAC) ...
Business Wire

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...